Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) has announced that CEO Dr. Joseph Tucker will participate in the H.C. Wainwright BioConnect Conference scheduled for January 10-13, 2022. His corporate presentation will be available on-demand starting January 10. The company focuses on developing innovative mental health and oncology treatments using psychedelic-derived molecules and synthetic cannabinoids. Enveric aims to address conditions like cancer-related distress and PTSD, supporting drug development for millions of patients worldwide.

NAPLES, Fla., Jan. 6, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C. Wainwright BioConnect Conference to be hosted virtually on January 10-13, 2022.

Dr. Tucker's corporate presentation will be available on-demand starting Monday, January 10^th. Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Enveric's management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at lk@hcwco.com, or KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-the-hc-wainwright-bioconnect-conference-on-january-10-13-2022-301455883.html

SOURCE Enveric Biosciences

FAQ

When will Enveric Biosciences present at the H.C. Wainwright BioConnect Conference?

Enveric Biosciences will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

Who is the CEO of Enveric Biosciences?

The CEO of Enveric Biosciences is Dr. Joseph Tucker.

What topics will Enveric Biosciences cover in its conference presentation?

Enveric Biosciences will discuss its innovative treatments for mental health and oncology, leveraging psychedelic-derived molecules and synthetic cannabinoids.

Where can I access the Enveric Biosciences presentation?

The presentation will be available on-demand starting January 10, 2022, as part of the H.C. Wainwright BioConnect Conference.

What is the primary focus of Enveric Biosciences?

Enveric Biosciences focuses on developing next-generation treatments for mental health and oncology using psychedelic-derived and synthetic cannabinoid molecules.